BioengineeringbioRxivPreprint
Pharmacokinetic profile of the synthetic mu-opioid receptor agonist Dermorphin-IRDye(R)800CW and its feasibility as a biomarker for opioid use disorder
Kimberley S. Samkoe, Rendall R. Strawbridge, Mark R. Spaller…·Jonathan Thomas Elliott
This paper develops a fluorescent peptide agonist to measure mu-opioid receptor occupancy in vivo and assesses its potential as a biomarker for opioid use disorder.
DOI 10.1101/2023.06.19.545627